# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Brookline Capital analyst Tyler Bussian initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price T...
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, to...
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value ind...
Jones Trading analyst Soumit Roy initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target o...
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, to...
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 t...